Fresenius Group Overview

Fresenius Kabi

Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.

Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection and processing of blood and cell components.

With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs over 38,000 people worldwide. In 2018 the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.

 

 

Key figures (IFRS)
€ in millions

2018

2017

Change

Sales

6,544

6,358

+ 3 %

EBIT

1,139

1,177

- 3 %

Net income

742

702

+ 6 %

Operating cash flow

1,040

1,010

+ 3 %

Capital expenditure/acquisitions

615

585

+ 5 %

R & D expenses 534

427

+ 25 %

Employees (December 31)

37,843

36,380

+ 4 %

  • Some figures adjusted for special items
  • Net income = Net income attributable to shareholders of Fresenius Kabi